All In Biotech

Drug Trial Radar · NCT01071070

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

A Phase 3b, Randomized, Active-Controlled, Single-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Injection in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects Receiving Hemodialysis

Last checked: Nov 19, 2026Latest source record: Jan 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

216

Actual

Start

Nov 2009

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Feb 19, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Conditions

  • Chronic Kidney Disease

Interventions

  • paricalcitolDrug

    Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone LevelsTime frame: Baseline to 12 Weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Site Reference ID/Investigator# 23483

    Beijing, China

  • Site Reference ID/Investigator# 23485

    Beijing, China

  • Site Reference ID/Investigator# 23482

    Beijing, China

  • Site Reference ID/Investigator# 23484

    Dalian, China

  • Site Reference ID/Investigator# 23486

    Guangzhou, China

  • Site Reference ID/Investigator# 23488

    Nanjing, China

  • Site Reference ID/Investigator# 37722

    Qingdao, China

  • Site Reference ID/Investigator# 23490

    Shanghai, China

  • Site Reference ID/Investigator# 25502

    Shanghai, China

  • Site Reference ID/Investigator# 23489

    Shanghai, China

  • Site Reference ID/Investigator# 23487

    Shanghai, China

  • Site Reference ID/Investigator# 35822

    Wenzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.